SAT413 Feminising Gender Affirming Hormone Therapy Prolongs QTc Interval

Disclosure: L. Angus: Speaker; Self; Kirin Brewery. T. Lin: None. S. Leemaqz: None. M. Grossmann: None. J.D. Zajac: None. A.S. Cheung: None. Background: In trans people using feminising hormone therapy there is an increased risk of cardiovascular events including conduction disorders. It is known th...

Descripción completa

Detalles Bibliográficos
Autores principales: Angus, Lachlan, Lin, Tina, Leemaqz, Shalem, Grossmann, Mathis, Zajac, Jeffrey D, Cheung, Ada S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Transgender Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554701/
http://dx.doi.org/10.1210/jendso/bvad114.2084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554701/
http://dx.doi.org/10.1210/jendso/bvad114.2084

Ejemplares similares